Wishpond Technologies Ltd is a stock to watch with a new all-in-one marketing and sales solution on the market and more acquisitions potentially to come, according to analysts at PI Financial.
The Vancouver-based company received a ‘Buy’ rating and C$1.75 price target, up from C$1.50.
Immunic has caught the attention of market analysts with the release of positive data from the maintenance phase of its Phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).
The company on Wednesday said data from the maintenance phase of CALDOSE-1 showed a dose-linear increase in clinical remission as compared to the placebo at week 50.
Depressed lithium prices have caused Bank of America to downgrade US producer Albemarle to Underperform.
The bank also cut its earnings forecast for Albemarle and lowered its price target to $195 from $262.
Amazon.com needs to further reduce its headcount to improve its eCommerce margin, according to analysts at Oppenheimer.
“We believe AMZN's 25% underperformance versus Nasdaq LTM is being driven by share loss to Microsoft (MSFT) and lack of eCommerce profitability,” the analysts wrote in a note to clients.
Jersey Oil and Gas PLC’s farm-out deal announced earlier on Thursday is worth more than £4 a share, according to research from finnCap.
Describing the partnership with NEO Energy, one of the North Sea’s big operators, as "exciting news", the corporate broker then goes on to forensically break down the ultimate value of the transaction.
Bitfarms (TSX-V:BITF) received a ‘Speculative Buy’ rating and a $2 target price from analysts at Stifel GMP as the brokerage kicked off coverage of the low-cost crypto miner.
With a long-standing track record as a proof-of-work mining company, analysts at Stifel said Bitfarms has strategically established a footprint of 10 facilities across geographically diverse regions that provide access to sustainably low-cost, surplus electricity.
Analysts at Stifel GMP have reiterated their ‘Buy’ rating and C$3.75 price target for software-as-a-service (SaaS) company Kneat.com after it signed a three-year agreement with a division of a top 20 global pharmaceutical company for e-logbook management in its quality control laboratories.
Ireland-based Kneat designs and supplies proprietary software, sold mainly as a SaaS offering for the validation space with a focus on manufacturing for life sciences.
Futura Medical PLC (AIM:FUM, OTC:FAMDF)’s prelims were "broadly in with expectations", according to corporate broker Liberum, which repeated its ‘buy’ recommendation and 121p a share price target for the stock.
The results were notable in so much as they form a backdrop for the commercial push in 2023 for its key asset, Eroxon, a gel treatment for erectile dysfunction.
Gold has regained its glister, with the precious metal’s safe haven status reignited by recent problems in the global banking sector including the collapse of Silicon Valley Bank and Credit Suisse’s decline.
Weakness in the latest US economic data and rising expectations that the Federal Reserve may look to start cutting interest rates are the latest factors pushing gold towards its all-time high of $2,075, according to City Index and FOREX.com market analyst Fawad Razaqzada.
ION Energy Ltd (TSX-V:ION, OTCQB:IONGF) is a 'Buy' for analysts at Couloir Capital as it makes progress at its projects in Mongolia - Baavhai Uul, and Urgakh Naran.
Noting that initial results of both projects returned a number of high-grade lithium highlights suggesting large base metal potential, the firm reiterated a 'Buy' rating and raised its fair value per share estimate to $1.45 per share from $1.12 per share, in a noted to clients.
Rathbones Group PLC (LSE:RAT, OTC:RTBBF) synergy and earnings-per-share (EPS) targets are “certainly achievable,” said Barclays, after the wealth manager announced it would be acquiring Investec’s UK arm.
The company is aiming to deliver synergies of £60mln, of which £18mln will be derived from technology consolidation, £10mln from net interest income due to the migration of clients onto Rathbone’s platform and £32mln from other operations.
Corporate broker finnCap provided positive commentary around peer-reviewed research on one of Destiny Pharma PLC's (AIM:DEST, OTC:DTTYF) lead assets.
The report in Microbiology Spectrum assessed NTCD-M3’s potential efficacy in C. difficile infections treated with a next-generation antibiotic called fidaxomicin, which has been included in US clinical guidelines for CDI treatment.
Deutsche Bank repeated its ‘buy’ advice and 1,700p price target for shares in GSK PLC (LSE:GSK, NYSE:GSK) in an update which assessed the news flow around its Hepatitis B research.
Put simply, the latest research updates, both from the UK company and competitor Roche, make the author optimistic about GSK's potential in the Hepatitis B market.
Shore Capital analysts have reiterated their buy rating for Accesso Technology Group PLC (AIM:ACSO, OTC:LOQPF), a technology provider to theme parks and visitors attractions, following today’s impressive trading update that underscored a revenue beat and strong cash flows.
Shore cap upgraded its cash EBITDA for full-year 2023 by 7% to $24mln, with a forecast of 6.6% revenue growth.
Gaming Realms PLC (AIM:GMR, OTCQX:PSDMF)’s full-year trading statement released on Monday, April 3 was in line with expectations laid out in February, house broker Peel Hunt today stated.
Pre-tax profits hit £3.5mln in 2022, up 224% from £1.1mln in the previous year, as sales shot up by 27% year-on-year to £18.7mln.